Axogen, Inc. (AXGN)
Stock Price Chart
Key Info
| Market Cap | 542.74M |
| Revenue (ttm) | 103.10M |
| Net Income (ttm) | -28.91M |
| Shares Out | 40.08M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $13.54 |
| Previous Close | $13.35 |
| Change ($) | 0.19 |
| Change (%) | 1.42% |
| Day's Open | 13.99 |
| Day's Range | 13.20 - 13.99 |
| Day's Volume | 399,124 |
| 52-Week Range | 7.16 - 18.84 |
More Stats
| Market Cap | 542.74M |
| Enterprise Value | 468.70M |
| Earnings Date (est) | Oct 29, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 40.08M |
| Float | 36.21M |
| EPS (basic) | -0.73 |
| EPS (diluted) | -0.73 |
| FCF / Share | -0.92 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.02M |
| Short Ratio | 2.98 |
| Short % of Float | 2.82% |
| Beta | 0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 5.26 |
| PB Ratio | 4.47 |
| Revenue | 103.10M |
| Operating Income | -30.29M |
| Net Income | -28.91M |
| Free Cash Flow | -36.44M |
| Net Cash | 74.04M |
| Net Cash / Share | 1.85 |
| Gross Margin | 86.67% |
| Operating Margin | -29.38% |
| Profit Margin | -28.00% |
| FCF Margin | -35.34% |
| ROA | -11.30% |
| ROE | -22.43% |
| ROIC | -29.50% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 107 | 83.94 | 60.43 | 41.11 | 27.33 | 16.82 | 10.95 | 7.69 | 4.85 | 3.00 |
| Revenue Growth | 27.13% | 38.91% | 46.99% | 50.41% | 62.52% | 53.62% | 42.33% | 58.61% | 61.41% | - |
| Gross Profit | 89.36 | 71.01 | 51.12 | 34.64 | 22.48 | 13.38 | 8.51 | 5.73 | 2.42 | 1.63 |
| Operating Income | -31.41 | -20.50 | -7.95 | -8.13 | -9.27 | -9.80 | -9.59 | -7.80 | -6.97 | -4.48 |
| Net Income | -29.14 | -22.40 | -10.45 | -14.41 | -13.36 | -17.71 | -14.56 | -9.42 | -9.22 | -5.42 |
| Shares Outstanding | 39.24 | 37.13 | 33.32 | 30.70 | 26.08 | 17.72 | 13.50 | 11.09 | 3.70 | 0.84 |
| Earnings Per Share | -0.74 | -0.60 | -0.31 | -0.47 | -0.51 | -0.99 | -1.08 | -0.85 | -2.77 | -8.35 |
| Operating Cash Flow | -19.87 | -17.86 | -9.24 | -11.24 | -13.05 | -10.45 | -10.44 | -8.66 | -7.08 | -3.94 |
| Capital Expenditures | -4.66 | -6.28 | -1.11 | -0.93 | -0.41 | -0.54 | -0.18 | -0.05 | -0.02 | - |
| Free Cash Flow | -24.54 | -24.14 | -10.34 | -12.17 | -13.46 | -10.99 | -10.62 | -8.71 | -7.10 | -3.94 |
| Cash & Equivalents | 103 | 123 | 36.51 | 30.01 | 25.91 | 8.22 | 20.07 | 13.91 | 8.19 | 1.80 |
| Total Debt | 1.74 | 0.06 | 24.55 | 24.31 | 24.70 | 25.09 | 25.36 | 21.58 | 4.84 | 8.42 |
| Net Cash / Debt | 101 | 123 | 11.96 | 5.70 | 1.21 | -16.87 | -5.29 | -7.67 | 3.35 | -6.62 |
| Assets | 155 | 160 | 58.88 | 46.36 | 36.70 | 16.40 | 27.68 | 20.23 | 12.50 | 6.41 |
| Liabilities | 22.49 | 13.19 | 33.69 | 31.44 | 28.50 | 27.65 | 27.55 | 23.06 | 6.42 | 18.11 |
| Book Value | 132 | 147 | 25.18 | 14.92 | 8.20 | -11.25 | 0.14 | -2.83 | 6.07 | -27.11 |
Company Profile
Company Details
| Full Name | Axogen, Inc. |
| Country | United States |
| Employees | 371 |
| CEO | Karen L. Zaderej |
Stock Information
| Ticker Symbol | AXGN |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NASDAQ: AXGN |
Description
AxoGen, together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.